Lundbeck’s potential first-in-class therapy for migraine prevention enters advanced clinical stage
PROCEED, a clinical phase IIb dose-finding trial will assess the efficacy and safety of subcutaneously administered Lu AG09222 in migraine prevention.H. Lundbeck A/S (Lundbeck) announced the advancement of the clinical development of Lu AG09222 for migraine prevention with the initiation of PROCEED, a randomized, double-blind, phase IIb, dose-finding trial to assess efficacy and safety of multiple subcutaneously administered doses. The PROCEED trial builds on the positive results of the HOPE phase IIa Proof-of-Concept trial demonstrating efficacy of intravenously administered Lu AG09222